Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Down 5.4% in December

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 537,700 shares, a drop of 5.4% from the December 15th total of 568,400 shares. Approximately 2.5% of the company’s shares are sold short. Based on an average trading volume of 252,500 shares, the days-to-cover ratio is presently 2.1 days.

Institutional Investors Weigh In On Carisma Therapeutics

A number of large investors have recently bought and sold shares of CARM. Barclays PLC lifted its stake in Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the period. Wexford Capital LP lifted its holdings in Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after acquiring an additional 15,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Carisma Therapeutics during the 2nd quarter worth about $40,000. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CARM. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th. Baird R W downgraded Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. BTIG Research cut Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Finally, Evercore ISI reissued an “in-line” rating and set a $0.70 price target (down from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.94.

Carisma Therapeutics Stock Down 3.5 %

NASDAQ CARM traded down $0.02 during trading on Friday, hitting $0.44. The company’s stock had a trading volume of 162,806 shares, compared to its average volume of 341,444. The company has a market cap of $18.40 million, a PE ratio of -0.28 and a beta of 1.56. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The business’s 50 day simple moving average is $0.63 and its 200-day simple moving average is $0.90. Carisma Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $2.77.

Carisma Therapeutics (NASDAQ:CARM) last issued its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). The company had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. On average, equities analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.